Maria Curras-Freixes
Overview
Explore the profile of Maria Curras-Freixes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monteagudo M, Calsina B, Salazar-Hidalgo M, Martinez-Montes A, Pineiro-Yanez E, Caleiras E, et al.
Best Pract Res Clin Endocrinol Metab
. 2024 Sep;
38(6):101931.
PMID: 39218714
Pheochromocytomas and paragangliomas are rare neuroendocrine tumours. Around 20-25 % of patients develop metastases, for which there is an urgent need of prognostic markers and therapeutic stratification strategies. The presence...
2.
Moreno-Cabrera J, Feliubadalo L, Pineda M, Prada-Dacasa P, Ramos-Muntada M, Del Valle J, et al.
Database (Oxford)
. 2024 Jul;
2024.
PMID: 38965703
Accurate classification of genetic variants is crucial for clinical decision-making in hereditary cancer. In Spain, genetic diagnostic laboratories have traditionally approached this task independently due to the lack of a...
3.
Calsina B, Pineiro-Yanez E, Martinez-Montes A, Caleiras E, Fernandez-Sanroman A, Monteagudo M, et al.
Nat Commun
. 2023 Feb;
14(1):1122.
PMID: 36854674
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown, hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show by genomic profiling of a large cohort of mPPGLs that...
4.
Cascon A, Calsina B, Monteagudo M, Mellid S, Diaz-Talavera A, Curras-Freixes M, et al.
J Mol Endocrinol
. 2022 Dec;
70(3).
PMID: 36520714
The genetics of pheochromocytoma and paraganglioma (PPGL) has become increasingly complex over the last two decades. The list of genes involved in the development of these tumors has grown steadily,...
5.
Marchena-Perea E, Salazar-Hidalgo M, Gomez-Sanz A, Arranz-Ledo M, Barroso A, Fernandez V, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230663
Around 50% of the familial breast cancer (BC) cases are estimated to be caused by germline variants in known low-, moderate-, and high-risk susceptibility genes, while the other half is...
6.
Montero-Conde C, Leandro-Garcia L, Martinez-Montes A, Martinez P, Moya F, Leton R, et al.
Clin Transl Med
. 2022 Aug;
12(8):e1001.
PMID: 35979662
Background: Comprehensive molecular studies on tumours are needed to delineate immortalization process steps and identify sensitive prognostic biomarkers in thyroid cancer. Methods And Results: In this study, we extensively characterize...
7.
Calvete O, Reyes J, Valdes-Socin H, Martin P, Marazuela M, Barroso A, et al.
Cells
. 2021 Dec;
10(12).
PMID: 34944008
Autoimmune polyendocrine syndrome (APS) is assumed to involve an immune system malfunction and entails several autoimmune diseases co-occurring in different tissues of the same patient; however, they are orphans of...
8.
Monteagudo M, Martinez P, Leandro-Garcia L, Martinez-Montes A, Calsina B, Pulgarin-Alfaro M, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638246
One of the main problems we face with PPGL is the lack of molecular markers capable of predicting the development of metastases in patients. Telomere-related genes, such as and have...
9.
Calsina B, Castro-Vega L, Torres-Perez R, Inglada-Perez L, Curras-Freixes M, Roldan-Romero J, et al.
Theranostics
. 2019 Aug;
9(17):4946-4958.
PMID: 31410193
: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that present variable outcomes. To date, no effective therapies or reliable prognostic markers are available for patients who develop metastatic PPGL...
10.
Remacha L, Pirman D, Mahoney C, Coloma J, Calsina B, Curras-Freixes M, et al.
Am J Hum Genet
. 2019 May;
104(5):1008-1010.
PMID: 31051110
No abstract available.